Key facts
- Vitract’s last known valuation is $330K (Apr 2022).
- It has raised $1.1M; the latest was Early Stage VC in Oct 2025.
- Notable investors include Techstars, University of Toronto, University of Toronto Entrepreneurship, Roosh Ventures, W Fund — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Vitract
- ·The full record, as it builds
Funding rounds
No funding rounds for Vitract are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Vitract
Developer of a microbiome technology with personalized nutrition intended to improve digestive health, metabolism, immunity, and mental wellness. The company's technology uses genomic sequencing to identify bacterial groups and metabolites that contribute to your gut health, and brain tests the gut and provides personalized suggestions from the technology to optimize gut health, enabling patients to have a gut microbiome treatment report that health care providers and patients can leverage.
- Sector
- Healthcare
- HQ
- Dover, DE, United States
- Founded
- 2022
- Employees
- 10
- Website
- vitract.com/
- Ownership
- Privately Held (backing)
Vitract doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Vitract shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Vitract in its N-PORT filings yet. We sweep new filings monthly.